322,955 research outputs found
Permanere nella transizione. Progetto di riqualificazione urbana dell’asse ferroviario e del tessuto a ridosso dell’agorà
No full text
Une ballade jazz en images: Il Trombettiere de Milo Manara et David Riondino
No full textLe Trombettiere est un récit illustré par Milo Manara et écrit sous forme de ballade par le musicien David Riondino. Basé sur la figure historique de Giovanni Martini (1852-1922) qui fut le trompettiste du générale Custer, l’ouvrage retrace les vagabondages et les rencontres musicales de ce musicien-soldat qui traversa le monde et qui peut être considéré comme l'un des précurseurs du jazz. L’article analyse le projet artistique élaboré par Riondino et Manara qui traverse le melting-pot musical du début du XXe siècle. Il expose les principes de collaboration artistiques, les méthodes de composition et d’improvisation poétique et visuelle de cette œuvre plurilinguistique
Impact of chemotherapy on venous thromboembolism: comment to: regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study
No full textGender differences in cancer-associated venous thromboembolism
No full textVenous thromboembolism (VTE) is a commonly diagnosed multifactorial condition with significant morbidity and mortality, occurring in up to 20% of cancer patients. Indeed, patients with cancer are in a higher pro-thrombotic state due to alterations in their haemostatic- coagulative system, stasis and blood flow slowdown, endothelial dysfunction, vascular inflammation and platelet activation. Moreover, several cancer-dependent factors can sum up to trigger a first episode of VTE or to cause its recurrence in the course of anticoagulant treatment. Such a pro-thrombotic condition is further worsened by additional favoring risks such as immobilization, infection, surgery, or insertion of a central venous catheter, and anti-cancer therapy. Furthermore, in the secondary prevention setting, the anticoagulant therapy is accompanied by a high incidence of bleeding complications. Given the above, understanding and identifying the factors associated with the incidence and clinical outcome of VTE in cancer patients might be of great value in the prevention and management of VTEattributable complications, including death. Differences associated to gender on cancerrelated VTEs are not yet fully defined; many of the studies that addressed the question have been biased by erroneous/non homogeneous inclusion criteria. In the present review, we analyzed the potential differences in VTEs occurrence in cancer patients, by reporting the most significant findings in the recent literature. The identification of a differential clinical approach according to patient sex, might prompt the design of personalized treatment options tailored and optimized according to algorithms for oncological VTE prevention
Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review
No full textRenal cell carcinoma (RCC) associated with anaplastic lymphoma kinase (ALK) gene rearrangements (ALK-RCC) is currently considered an “emerging or provisional” tumor entity by the last World Health Organization classification published in 2016. Although several studies assessing ALK-RCC’s clinical and histological characteristics have been published in recent years, only a few publications have evaluated the activity of ALK inhibitors (ALK-i) in this subgroup of patients. Considering the well-recognized efficacy of this evolving class of targeted therapies in other ALK-positive tumors, we conducted a systematic review to evaluate the reported activity of ALK-i in the ALK-RCC subtype. MEDLINE was searched from its inception to 7 January 2022 for case reports and case series on adult metastatic ALK-RCC patients treated with ALK-i whose therapeutic outcomes were available. A virtual cohort of ALK-RCC patients was created. Our results showed a favorable activity of first- and second-generation ALK-i in pretreated ALK-RCC patients in terms of either radiological response or performance status improvement. We hope that the present work will prompt the creation of large, multi-institutional clinical trials to confirm these promising early data
Predicting VTE in cancer patients: Candidate biomarkers and risk assessment models
No full textRisk prediction of chemotherapy-associated venous thromboembolism (VTE) is a compelling challenge in contemporary oncology, as VTE may result in treatment delays, impaired quality of life, and increased mortality. Current guidelines do not recommend thromboprophylaxis for primary prevention, but assessment of the patient’s individual risk of VTE prior to chemotherapy is generally advocated. In recent years, efforts have been devoted to building accurate predictive tools for VTE risk assessment in cancer patients. This review focuses on candidate biomarkers and prediction models currently under investigation, considering their advantages and disadvantages, and discussing their diagnostic performance and potential pitfalls
Effects of picotamide on the calcium mobilization and phospholipase C activation in human platelets.
No full textThe effect of picotamide (G137 or N,N'-bis-3-picolyl-4-methoxyisophthalamide), a dual thromboxane A(2) (TxA(2)) synthetase inhibitor/TxA(2) endoperoxide receptor antagonist, on the phospholipase C (PLC) activation and calcium mobilization in human platelets stimulated by arachidonic acid (AA) and TxA(2) receptor synthetic agonist U46619, has been studied. Preincubation with picotamide (10(-4) M) for 1 and 3 min significantly reduced (p<0.03 and p<0.005 respectively) the calcium concentration changes induced in gel-filtered platelets (GFP(s)) by U46619 125 nM and 250 nM. Picotamide also reduced the calcium concentration changes induced in GFP(s) by AA 75 and 150 mu M and by ADP 5 and 10 mu M. In thrombin degranulated platelets picotamide inhibited the effect of U46619 up to 500 nM. The PLC activation, as indicated by inositol-1,3,4 P-3 (Ins 1,3,4 P-3) formation in response to U46619 250 nM and AA 150 mu M was also inhibited by picotamide. These results may suggest a dual effect of picotamide on the receptor/effector systems through which TxA(2) mediates platelet activation
- …
